Skip to main content
Clinical Trials/NCT05067049
NCT05067049
Unknown
N/A

Evaluation of the Impact of a Connected Application on the Follow-up of Patients Treated for Glial Lesions Operated: a Prospective, Randomized Study

Ramsay Générale de Santé1 site in 1 country66 target enrollmentFebruary 1, 2019

Overview

Phase
N/A
Intervention
Not specified
Conditions
Quality of Life
Sponsor
Ramsay Générale de Santé
Enrollment
66
Locations
1
Primary Endpoint
Assessment of the impact of the connected mobile monitoring application on the quality of life, at 6 months, of patients treated for an operated glioma.
Last Updated
4 years ago

Overview

Brief Summary

This study is to evaluate the efficacy of a mobile app for monitoring the quality of life of patients but also on detection delay of side effects and/or complications linked to the therapeutic management. This allow to adapt their care more quickly, through a prospective randomized study. The impact of this connected monitoring of patients' anxiety will also be evaluated in this study as well as the time taken by the medical team to manage alerts generated by this application.

Registry
clinicaltrials.gov
Start Date
February 1, 2019
End Date
February 2022
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Male or female over 18 years old without upper age limit.
  • Subject operated for a non-recurrent glioma (grade II or III or IV glioma / glioblastoma) according to the WHO classification 2016;
  • Subject with a connected support (smartphone,...) to download the connected tracking application.
  • Unprotected adult within the meaning of the law
  • Subject affiliated to a health insurance scheme
  • Subject having signed an informed written consent

Exclusion Criteria

  • Minor subject, pregnant or breastfeeding woman;
  • Subject under a measure of legal protection, guardianship or deprived of liberty by judicial or administrative decision;
  • Antipsychotic treatment (neuroleptic or lithium)
  • Subjects with documented cognitive disorders (Alzheimer, other dementia)
  • Subject with a personal medical history of psychiatry
  • Subject unable to complete a questionnaire on his own (inability to read French language , severe cognitive disorders)
  • Medical contraindication to performing an MRI (pace-maker) or scanner;
  • Subject refusing to sign informed consent.

Outcomes

Primary Outcomes

Assessment of the impact of the connected mobile monitoring application on the quality of life, at 6 months, of patients treated for an operated glioma.

Time Frame: 6 months

The primary outcome measure is the difference in quality of life assessed by the QLQ-BN20 scale at 6 months, compared to inclusion. This scale is made up of 20 items which are grouped into 4 dimensions (future uncertainty, visual disorder, motor dysfunction, and communication deficit) and 7 isolated items.

Study Sites (1)

Loading locations...

Similar Trials